MARKET

GNLX

GNLX

Genelux Corp
NASDAQ
6.22
+0.20
+3.34%
Opening 09:38 03/28 EDT
OPEN
5.94
PREV CLOSE
6.02
HIGH
6.22
LOW
5.90
VOLUME
8.04K
TURNOVER
0
52 WEEK HIGH
40.98
52 WEEK LOW
5.67
MARKET CAP
166.22M
P/E (TTM)
-5.6882
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GNLX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at GNLX last week (0311-0315)?
Weekly Report · 03/18 10:39
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Regulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. Assure Hldgs stock increased by 73.02% in the pre- market session. Telomir Pharmaceuticals and Bioventus also moved upwards.
Benzinga · 03/12 13:05
Weekly Report: what happened at GNLX last week (0304-0308)?
Weekly Report · 03/11 10:36
12 Health Care Stocks Moving In Friday's After-Market Session
Talphera (NASDAQ:TLPH) shares moved upwards by 15.6% to $1.3 during Friday's after-market session. The company's market cap stands at $3.4 billion. Genelux shares increased by 10.06% and Estrella Immunopharma stock rose 8.65%.
Benzinga · 03/08 21:31
Weekly Report: what happened at GNLX last week (0226-0301)?
Weekly Report · 03/04 10:39
Weekly Report: what happened at GNLX last week (0219-0223)?
Weekly Report · 02/26 10:48
Weekly Report: what happened at GNLX last week (0212-0216)?
Weekly Report · 02/19 10:49
More
About GNLX
Genelux Corporation is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from solid tumor types. Its advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. The Company is focused on Phase II clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Its Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT) Immunotherapy is an indication-agnostic personalized anti-cancer therapy designed to safely maximize the number and effect of cancer neoantigen-specific effector T cells within cancer tissues. Its animal health product candidate, V-VET1, is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus that is a naturally attenuated isolate.

Webull offers Genelux Corp stock information, including NASDAQ: GNLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNLX stock methods without spending real money on the virtual paper trading platform.